Ivosidenib as Post-HSCT Maintenance for AML

This study is testing whether ivosidenib — a targeted drug that blocks a mutated enzyme called IDH1 — can prevent relapse when given as maintenance therapy after a stem cell transplant in people with a specific type of blood cancer (AML) that has an IDH1 mutation. **You may be eligible if...** - You are between 18 and 75 years old - You have acute myeloid leukemia (AML) with an IDH1 mutation (detected at any prior point) - You are planning to undergo an allogeneic (donor) stem cell transplant - Your blood counts and organ function meet minimum requirements - You are in reasonably good functional condition (ECOG 0-2) **You may NOT be eligible if...** - You do not have an IDH1 mutation in your leukemia - You have significant organ dysfunction - You have conditions that would make the drug or transplant unsafe Talk to your doctor to see if this trial is right for you.